App-Quantinova.ai

The RISC nomogram (RN) to predict overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line platinum-based combination chemotherapy (CT).

Andrea Necchi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

N/A

ToTem: A phase Ib trial of temisirolimus with gemcitabine and cisplatin.

Simon Pacey - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Gemcitabine

Outcomes of patients treated with paclitaxel, ifosfamide and cisplatin (TIP) for relapsed germ cell tumour (GCT).

Mariam Jafri - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Ifosfamide

Treatment of advanced seminoma with 3 cycles of etoposide-cisplatin chemotherapy (EP120): A single-centre retrospective cohort study.

Ankit Rohit Rao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Seminoma

Etoposide

Factors predicting renal function after partial nephrectomy: A multi-institutional analysis of data from the SIB working group.

Brian R. Lane - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Surgeon assessment of volume preservation (SAVP) performed before or after partial nephrectomy to predict post-operative renal function.

Michael Klingler - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

N/A

10 year outcomes from a single-centre experience of sunitinib and pazopanib as first-line treatment of metastatic renal-cell carcinoma (mRCC).

Shien Chow - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Pazopanib

Management of non metastatic castrate resistant prostate cancer (NM-CRPC), results of a UK wide national survey.

Muhammad Farooq Latif - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

N/A

Tolerability and efficacy of lower dose of cabazitaxel (=/< 20mg/m2) in castration-refractory prostate cancer (CRPC).

Sarah Taylor - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Cabazitaxel

Circulating AR copy number and outcome to enzalutamide in patients with metastatic castration-resistant prostate cancer after docetaxel.

Samanta Salvi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Enzalutamide

Does the choice of hormone therapy affect medium-term outcomes following radical external beam radiotherapy for localized prostate cancer?

Ciara Lyons - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Bone Scan Index as an imaging biomarker to predict overall survival in the Zeus/SPCG11 study.

Mariana Reza - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Results of the first thousand patients from a multidisciplinary prostate cancer clinic.

Pandora Rudd - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Impact of pre-treatment neutrophil-lymphocyte ratio on outcomes in men receiving radical external beam radiotherapy for localised prostate cancer.

Ciara Lyons - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Concurrent boost technique in prostate IMRT and accuracy of planning target volume (PTV) at the periphery.

Santhanam Sundar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Compassionate use study of TRC105 (Endoglin Antibody) in combination with bevacizumab (Bev) in patients (pts) with refractory and metastatic choriocarcinoma.

Neil S. Horowitz - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Choriocarcinoma

Bevacizumab

Modeling tumor size time course in platinum resistant/refractory ovarian cancer patients treated with vanucizumab.

Christophe Boetsch - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gynaecological cancer

N/A

Evaluating a novel oncologist-led BRCA1/2 mutation (BRCAm) testing counseling model for patients with ovarian cancer: Interim results from the ENGAGE study.

Gloria S. Huang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peritoneal cancer

N/A

Improved survival of stage 4 high grade ovarian cancer patients as staged by positron emission tomography (PETCT), who undergo chemotherapy (with a good PETCT response) and debulking surgery as seen in a prospective study in our cancer institution.

Chit Cheng Yeoh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gynaecological cancer

N/A

Sustained Gas6/AXL signaling network in the mes subtype of ovarian cancer as a molecular subtype specific therapeutic target.

Ruby Yun-Ju Huang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gynaecological cancer

N/A

Filters

45280 Abstracts